Earnings ·
Dermata Therapeutics reports Q3 net sales of $74,000 following first commercial product launch
DRMADermata Therapeutics, Inc.
Dermata Therapeutics reported net sales of $74,000 and a gross profit of $40,000 for the quarter ended September 30, 2026, marking its first revenue from the August 25 launch of Tome Foundational Treatment. The company incurred a net loss of $2.8 million as selling, general and administrative expenses rose to $2.8 million due to commercialization activities, while R&D costs fell to $143,000. Cash reserves decreased by $2.5 million to $5.0 million, with management stating current funds are sufficient through the first quarter of 2027. Dermata Therapeutics is a science-driven leader in dermatologic solutions focused on the development and commercialization of consumer and professional skincare products.